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Introduction
It is now widely acknowledged that early diagnosis of 
rheumatoid arthritis (RA) and aggressive treatment to 
control disease activity oﬀ   er the highest likelihood of 
preserving function and preventing disability. RA is a 
chronic autoimmune disease characterized by poly-
articular inﬂ  ammation associated with synovitis, osteitis, 
and peri-articular osteopenia, often associated with 
erosion of subchondral bone and progressive joint space 
narrowing [1]. Th  ese features commonly lead to pro-
gressive joint damage, impaired function, and progressive 
disability [2-4]. Since roughly half of RA patients suﬀ  er 
disability within 10 years of diagnosis, it is critical to 
eﬀ   ectively treat the disease early to suppress inﬂ  am-
mation and prevent destruction of bone and joint 
cartilage [5,6]. Treatment is commonly determined by 
the extent or severity of disease activity, assessed by 
counting the number of swollen and tender joints, 
measuring patient-reported outcomes (for example, 
patient global quality of life assessment), and assaying 
acute phase responses, such as the erythrocyte sedi  men-
tation rate (ESR) and C-reactive protein (CRP) levels.
While inﬂ   ammation markers are clinically relevant, 
markers that reliably detect ongoing bone and cartilage 
damage are potentially more useful for timely monitoring 
of eﬃ   cacy of treatment. Joint inﬂ  ammation and damage 
are so far assessed by various imaging methods, including 
hand and feet radiographs, hand magnetic resonance 
imaging (MRI), and high-resolution ultrasound of 
speciﬁ   c joints [7]. Biochemical markers of bone and 
cartilage turnover are also receiving increasing attention 
in other conditions characterized by joint and/or skeletal 
inﬂ   ammation and damage [8]. Th  ey may provide an 
additional and potentially more sensitive method of 
detection of active bone and cartilage degradation that is 
likely to lead to structural damage in RA [0].
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© 2011 BioMed Central LtdAn evolving line of evidence suggests that markers 
associated with clinical response may not be the same 
biomarkers that predict risk of further joint damage, as 
veriﬁ  ed by radiological progression, and thus diﬀ  erent 
marker combinations are likely to be needed, with 
speciﬁ  c combinations selected for speciﬁ  c uses, poten-
tially contri  buting to personalized health care [10-12]. 
Prog  nostic markers could be divided into at least two 
categories: those that predict clinical response in terms 
of signs and symptoms of RA, and those that predict and 
monitor joint damage, as detected cumulatively by 
various imaging modalities, and ultimately demonstrated 
by the clinical manifestations of deformity and 
dys func tion.
Th  e aims of this review are to describe pathobiology 
that generates biochemical markers of joint metabolism/
damage in RA, including application in assay develop-
ment; to survey the current use of biochemical markers 
of joint damage in RA and some other relevant diseases; 
to discuss the limitations of some of these established 
biochemical markers, including the need for further 
research into serum and urine markers, to encourage 
optimal study designs and sample acquisition; to describe 
how biochemical markers may allow for diagnosis of 
patients who are experiencing joint damage with rapid 
degradation of bone and/or cartilage and thus are most in 
need of timely, aggressive treatment; and to discuss how 
advances in personalized health care, including mapping 
of a patient’s speciﬁ  c biomarker and clinical proﬁ  le, will 
allow treatment selection according to those that will be 
most likely to beneﬁ  t.
Pathobiological processes associated with 
progression of joint damage, and biochemical 
markers of joint damage
Th  e  diﬀ  erent cellular phenotypes involved in joints (osteo-
blasts, osteoclasts, chondrocytes, macrophages, B cells, 
T  cells, ﬁ   brobast-like synoviocytes and macro  phages) 
play distinct complex and inter-related roles in the patho-
genesis and progression of RA joint damage [13]. Sub-
chondral bone erosion, sclerosis and articular cartilage 
degradation leading to joint space narrowing are central 
features of joint damage in RA. Synovitis and osteitis 
associated with osteoclast activation and degra  da  tion of 
bone by matrix metalloproteinases (MMPs) and cathep  sin 
K appear to precede erosions visualized by MRI or radio-
graphy [13-17]. Further, cytokines such as IL-1, TNF-
alpha, IL-6, and IL-17 stimulate chondrocyte activa  tion 
and expression of MMPs and aggrecanases, resulting in 
articular cartilage degradation. Th  us, a wide range of 
processes contribute to the pathobiology of joint damage 
that eventually leads to joint failure [3,10,11,14] (Figure 1). 
A detailed discussion of the cellular inter  actions and 
molecular pathways involved in bone and cartilage 
damage in RA is out of the scope of this review, and has 
been documented elsewhere [3,10,12-15,17,].
Th   e generation of a tissue-speciﬁ  c biochemical marker is 
presented in Figure 2. Th   e enzymes in the inﬂ  amed joint 
generate speciﬁ  c biochemical metabolic products from the 
extracellular matrix; the actual protein frag  ments of type II 
collagen and aggrecan that are the result of pathobiological 
actions in the joint are schematically presented in Figure 3. 
Th  ese speciﬁ  c products, which will be described, can be 
measured [7,18], facilitating assess  ment of various 
molecular, cellular and pathophysio  logical processes in the 
joint. Each marker may provide unique insights into the 
pathology of the disease by allowing quantitative 
information on the level of disease activity in terms of 
target tissue damage, on the action of cytokines driving 
disease progression, and on the speciﬁ  c mode of action 
and potential eﬃ   cacy of therapeutic interventions. Th  ese 
features provide perspective for the characterization of the 
ongoing pathobiology using sets of biomarkers that 
potentially describe the type of damage occurring. A 
combination of speciﬁ   c biomarkers may thus provide 
more detailed and accurate information on joint pathology 
and ongoing structural damage than individual markers.
As described above, the biochemical markers may be 
useful by providing quantitative information on the patho-
logy and unique processes associated with joint damage in 
RA. In addition, from a patient-management perspective, 
the biochemical markers may be useful for the diagnosis of 
patients with ongoing, active damage to, and degradation 
of, bone and/or cartilage, for early detection and 
monitoring of response to treatment, and for personal  izing 
health care. Patients with such ongoing, active damage and 
degradation of bone and/or cartilage might be classiﬁ  ed as 
‘rapid progressors’ and are those most in need of eﬀ  ective 
treatment. Th   ey may be identiﬁ  ed by detection of abnor-
mal serum and/or urine levels of bone, synovium and/or 
cartilage degradation/turnover markers, prior to estab-
lished, irreversible damage being identiﬁ  ed using one or 
more imaging modalities. Early detection and monitor  ing 
of response to treatment potentially provides more rapid 
veriﬁ  cation of control of joint damage than improve  ment 
in clinical symptoms or imaging changes, since a minimum 
of 6 months is needed to ascertain radiological progres-
sion, although newer MRI technologies may detect changes 
in osteitis and synovitis within several months. Health care 
can be personalized by identifying patients most likely to 
respond or not to a particular treatment, thus enabling 
informed selection of an appropriate thera  peutic agent, as 
well as timely veriﬁ  cation of its expected eﬃ   cacy.
Biochemical markers as predictors of progression 
of structural damage
Biochemical markers of bone turnover have been used as 
standard practice to measure the eﬀ  ects of therapy in 
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Page 2 of 20osteoporosis (OP), a slowly progressing condition [17]. 
For example, early changes in CTX-I (C-terminal telo-
peptide of collagen type I), a marker of bone resorption, 
and changes in osteocalcin, a marker of bone formation, 
can be used to predict increases in bone mineral density 
[8]. In contrast to imaging techniques, biochemical 
markers of bone and cartilage turnover, measured in 
serum or urine samples collected during fasting or as 
second morning void specimens, show clinically relevant 
changes over a larger range compared with the impre-
cision of the assay (8% to 10%) [17]. A typical decrease of 
50 to 80% or an increase of 100 to 200% is observed in the 
level of biochemical markers within days to weeks after 
initiation of treatment with anti-resorptive or anabolic 
drugs [17]. However, the respective change in bone mass 
ranges from 6 to 7% after 2 years of bisphosphonate 
therapy, which is a comparatively small increment 
relative to a precision error of 1 to 2% for bone mineral 
density (BMD) measurements, as reviewed recently [17], 
and thus could be considered inferior to the dynamic 
range observed with biochemical markers. Because 
biochemical markers are sensitive and dynamic indicators 
of tissue turnover, they have the potential to provide 
information on treatment eﬃ   cacy more rapidly than a 
variety of imaging methods (Figure 4) [16]. Th  is use of 
biochemical markers of bone turnover has so far been 
validated in OP, as have markers of cartilage turnover in 
osteoarthritis (OA) [8,17]. In OP, a dynamic biochemical 
marker such as CTX-I changes within days of initiating 
treatment with anti-resorptives or the anti-receptor 
activator of NF-kB ligand (RANKL) drug denosumab, 
whereas BMD im  prove  ments can only be reliably 
detected over 6 to 12 months. Similarly, urinary CTX-II 
(C-terminal telo  peptide of collagen type II) levels have 
been shown to predict articular cartilage degradation 
[19] in OA. Th   e same markers have been examined in RA 
Figure 1. Cells involved in rheumatoid arthritis joint damage include osteoblasts, osteoclasts, chondrocytes, monocytes/macrophages, 
B cells, T cell subsets (including regulatory T cells), and fi  brobast-like synoviocytes, each playing distinct complex and interrelated 
roles in its pathogenesis and progression. This cellular diversity highlights the need for biomarkers for a range of pathological events. Diff  erent 
markers of cell signaling (for example, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG)), cell diff  erentiation, collagen I and 
II degradation and turnover, matrix production, and matrix degradation and the enzymes mediating that degradation may be measured. The 
pleiotrophic cytokines IL-1β, TNF-α, IL-6, and IL-17, as well as several other cytokines and chemokines, are associated with the induction of matrix 
metalloproteinases (MMPs), as well as osteoclast diff  erentiation, activation and release of cathepsin K [36]. This range of interactive events leads 
to progressive joint destruction if not managed attentively, for example, using tight control strategies [15,18,22,104,140,141]. C2C, type II collagen 
fragment; CIIM, MMP mediated type II collagen degradation; CTX-I, C-terminal telopeptide of collagen type I; CTX-II, C-terminal telopeptide of 
collagen type II. 
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degradation and CTX-I as a marker of bone (collagen I) 
degradation in RA at 4 and 12 weeks have been demon-
strated to predict joint damage (Tables 1, 2 and 3).
Research eﬀ  orts are underway to apply these principles 
to proactive management of RA to enhance the detection 
and prevention of joint damage. X-ray imaging is the 
standard technique for diagnosis and measurement of 
eﬃ   cacy of therapies aimed at inhibiting joint damage. 
Further eﬀ  orts are ongoing to validate the use of MRI in 
this process, and even combine the use of biochemical 
markers and imaging modalities [7,21]. In RA, joint 
damage characterized by subchondral bone erosions and 
joint space narrowing, rather than BMD as in OP, is 
measured by various scoring methods applied to X-rays 
of hands and feet. However, X-ray imaging in both 
diseases is encumbered by rather low precision and could 
conceivably beneﬁ  t from combination with biochemical 
marker analysis (Figure 4).
Need for biochemical markers to facilitate 
treatment decisions
Recently, three biological agents with novel mechanisms 
of action, rituximab, abatacept and tocilizumab, have 
become available for the treatment of RA, adding to the 
armamentarium already containing the approved TNF-α 
inhibitors (inﬂ   iximab, etanercept, adalimumab, 
certoli  zu  mab and golimumab). Clinical studies with these 
agents have demonstrated that they are eﬀ  ective in RA 
patients who did not respond to treatment with at least 
one disease-modifying antirheumatic drug (DMARD) 
and/or TNF inhibitor. In the absence of head-to-head 
trials, the use of speciﬁ  c biochemical markers may aid in 
diﬀ  erentiating the onset and/or the magnitude and even 
duration of eﬃ     cacy of the diﬀ   erent drugs, and in 
understanding which patient may respond best to a given 
intervention. Th  e early identiﬁ  cation of responders and 
non-responders to the increasing range of treatments for 
RA, a disease recognized to lead to loss of function and 
disability if not aggressively treated, will prove valuable to 
patients, regulators, healthcare providers and payers. Th  e 
emphasis in RA management today is on early diagnosis 
and treatment to prevent the progressive joint deteri  ora-
tion predominantly driven by inﬂ  ammation  [22-24]. 
Selecting the most appropriate intervention has become 
increasingly complex because, for example, combinations 
of some therapies have proven more eﬀ  ective in clinical 
trials than single agents alone and also because diﬀ  erent 
interventions may be more appropriate than others 
according to the stage and risk of disease progression in 
individual patients. In some patients, joint damage pro-
gresses slowly over time and then begins to progress in a 
more rapid and dynamic fashion. In those where inﬂ  am-
mation is more severe, structural damage can occur 
Figure 2. A graphic representation of the generation of pathology-relevant neoepitopes of infl  amed joint cartilage. The enzymes presently 
receiving the most attention are the matrix metalloproteinases (MMPs) and aggrecanases (ADAM-TS (a disintegrin and metalloproteinase with 
thrombospondin motifs)). The most abundant cartilage proteins are collagen type II and aggrecan. Protease-generated fragments of collagen type 
II and aggrecan produced through the action of these important enzymes, which may be relevant molecules in tissue destruction, can be used to 
monitor tissue turnover. These fragments, such as C-terminal telopeptide of type II collagen (CTX-II), may be used in clinical settings, in preclinical 
models and in simple ex vivo and in vitro systems. Figure adapted with permission from [8].
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quently, the greatest opportunity to change the course of 
the disease could be through the identiﬁ  cation of those 
patients who either have, or are at risk of developing, 
rapidly progressive disease. Using biomarkers to predict 
risk and response to therapy will not only aid the 
selection of an appropriate, eﬀ  ective intervention for the 
individual but will also protect patients with less severe 
disease from possible aggressive over-treatment and 
toxicities, and may have a signiﬁ  cant inﬂ  uence on allo-
cation of health care resources. Several biological 
markers and clinical indicators have been discovered to 
identify such patients.
Biochemical markers of joint damage
Currently, there is no single clinical or laboratory 
characteristic that identiﬁ   es RA patients with rapidly 
progressing joint damage and systemic bone eﬀ  ects. Th  e 
best-characterized predictors of risk for rapid progression 
are the number of swollen joints and levels of acute-
phase reactants such as CRP and ESR. Th   is is not surpris-
ing because swollen joints are a clinical manifestation of 
synovitis, and the acute-phase response acts as a 
biomarker of pro-inﬂ  ammatory cytokine production. It is 
well documented that elevated CRP is associated with 
increased risk of radiological progression in RA [24,25], 
and correlation between synovitis and subchondral bone 
Figure 3. Protease-generated neoepitopes in aggrecan and collagen type I and II. (a,b) The amino- and carboxy-terminal pro-peptides PINP 
(amino terminus propeptide of type I procollagen), PICP (carboxyl terminus propeptide of type I procollagen), PIINP (amino terminus propeptide 
of type II procollagen) and PIICP (carboxyl terminus propeptide of type II procollagen) in collagen type I (a) and collagen type II (b) are used to 
defi  ne protein formation, as they are released during formation of the matrix. (a) In contrast, the degradation markers ICTP (type I collagen; MMP 
mediated) and C-terminal telopeptide of type I collagen (CTX-I; cathepsin-K mediated) located in the carboxy-terminal telopeptide are found in 
body fl  uids after degradation of collagen type I. (b) The CTX-II (MMP mediated) degradation marker is located in the carboxy-terminal telopeptide 
in collagen type II. Coll 2-1, TIINE, C2C, and C2-3/4C are degradation markers located in the helix of collagen type II. (c) The aggrecan molecule is 
shown with the MMP cleavage sites (upward arrows) and ADAM-TS (a disintegrin and metalloproteinase with thrombospondin motifs) cleavage 
sites (downward arrows). CIIM is a novel MMP mediated type II collagen degradation marker [142]. Figure adapted with permission from [8].
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patients with high disease activity that manifests in high 
swollen joint counts and elevated CRP are immediately 
eligible for biologic therapy, those who also show ongoing 
degradation of joint structure proteins may beneﬁ  t from 
the most intensive therapy, especially if eﬃ   cacy can be 
detected early to manage beneﬁ  t and risk considerations 
[25]. Th   e focus of research into joint damage biomarkers 
has been the identiﬁ   cation of proteins that might be 
surrogates of whole tissue metabolism and of bone and 
cartilage loss. One approach to identifying pathologically 
relevant molecules is to combine tissue-speciﬁ  c protein 
markers with the pathological expression of proteolytic 
enzymes. Th  e action of enzymes on extracellular matrix 
components results in matrix degradation fragments, or 
neoepitopes. Th   e most abundant molecules in the articular 
cartilage extracellular matrix are collagen type II and 
aggrecan. Th   ese proteins are sequentially degraded when 
cartilage damage occurs in either RA or OA. Protease-
generated fragments of collagen type II and aggrecan 
produced by MMPs and aggrecanases (ADAM-TS) are 
considered relevant molecules in cartilage degra  da  tion 
[8] (Figure 3). Whole joint tissue pathophysiology may be 
assessed by the one or more markers of cartilage 
degradation, but these are only a subset of a larger panel 
of markers that provide information on bone and 
inﬂ  amed synovial tissue in the joint (Table 1).
As also described in Table 1, additional cartilage degra-
da  tion markers are becoming available, aimed at more 
accurate and precise detection of articular cartilage 
damage. Speciﬁ   c fragments of cartilage proteins have 
been identiﬁ  ed as speciﬁ  c markers of joint damage. Much 
of this work has been applied according to the US Food 
and Drug Administration critical path for the 
development of biochemical markers in translational 
research [8], where such markers may be applied in both 
preclinical and clinical research settings.
Joint turnover markers
Inﬂ  ammatory joint diseases such as RA lead to alterations 
in the metabolism of the articular cartilage and sub-
chondral as well as periarticular bone [30-35]. Unique 
markers have been developed, and others are under 
development, to reﬂ  ect diﬀ  erent pathobiologic processes. 
How these processes occur at diﬀ   erent stages in the 
patho  genesis, and result in unique metabolic products of 
joint inﬂ  ammation, is discussed in the sections below.
Cartilage turnover markers
Cartilage turnover normally occurs in a controlled 
fashion, with a balance between degradation and 
formation. However, in the inﬂ  amed joint, an imbalance 
is skewed towards degradation rather than formation 
[36]. Formation and degradation can be monitored by 
measuring several unique molecules generated during 
cartilage degradation and turnover [17]. Cartilage is pre-
domi  nantly composed of collagen type II (comprising 60 
to 70% of the dry weight of cartilage) and proteoglycans 
(10% of dry weight), of which aggrecan is the most 
abundant [37]. Th   e key mediators of cartilage degradation 
include the MMPs and the closely related aggrecanases, 
which are members of the ADAM-TS family [38,39]. 
Figure 4. Biochemical markers provide increased sensitivity to change compared with imaging techniques assessing joint space width 
(JSW). Figure adapted with permission from [16].
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Page 6 of 20Table 1. Biochemical markers of bone and cartilage turnover measurable in serum, urine and synovial fl  uid 
Assay Target molecule Short description
Evidence of 
potential 
usefulness 
KS/mAb OA-1 Aggrecan Cartilage degradation. Sandwich ELISA using mAb to keratan sulfate and mAb OA-1 to 
AGase neoepitope ARGSVIL [143]. Detection of fragments in human synovial fl  uid [143]
[143]
CS846 Aggrecan Cartilage turnover. mAb αHFPG-846 (IgM) recognizing chondroitin sulfate moieties on 
aggrecan. Manufacturer: Ibex, Canada
[144,145]
342-G2 Aggrecan Cartilage degradation. Sandwich ELISA using mAb AF28 binding to the neoepitope 
342FFGVG and monoclonal antibody F78 binding to G1/G2 for detection of MMP-
generated aggrecan fragments 
[45]
G1-G2 Aggrecan Cartilage turnover. Sandwich ELISA using mAb F78 binding to G1/G2 both as capture and 
detector antibody for detection of intact aggrecan and all aggrecan fragments carrying 
G1 and/or G2 
[45,146]
Serum CRP C-reactive protein General infl  ammation. CRP, an acute phase protein, the assay for which is highly sensitive 
to detect small changes in magnitude of infl  ammation 
[60,126, 
147-149]
COMP Cartilage oligomeric protein Cartilage turnover. Competition ELISA using polyclonal antibodies [58]. However, 
sandwich ELISA based on two monoclonal antibodies recognizing diff  erent antigenic 
determinants is described [150]. Manufacturer: AnaMar Medical, Sweden
[60,61, 
151-155]
PICP Carboxyl terminus propeptide of 
type I procollagen
Bone formation. RIA using polyclonal antibodies raised to fi  broblast PICP digested with 
bacterial collagenase [156]. Manufacturer: Orion Diagnostic, Finland
[156]
PINP Amino terminus propeptide of 
type I procollagen
Bone formation. RIA using polyclonal antibodies recognizing PINP [157]. Manufacturer: 
Orion Diagnostic, Finland. Electrochemiluminecense using mAbs to PINP. Manufacturer: 
Roche Diagnostics, Germany
[158]
CTX-I Type I collagen Bone resorption. A sandwich ELISA using mAb F1103 and F12, both binding to a 
cathepsin K-derived C-telopeptide neoepitope EKAHD-β-GGR, where D-β-G denotes 
an isomerized linkage between D and G [84]. Manufacturer: IDS, UK. Also available in an 
automated version (manufacturer: Roche Diagnostics, Germany)
[87-89]
NTX-I Type I collagen Bone resorption. EIA detecting a fragment of the N-telopeptide of type I collagen. 
Manufacturer: Inverness, US
[159] 
ICTP Type I collagen MMP-mediated type I collagen type degradation. RIA detecting a fragment of the 
C-telopeptide of type I collagen. Manufacturer: Orion Diagnostic, Finland
[81,160]
PIINP Amino terminus propeptide of 
type II procollagen
Cartilage formation. mAb recognizing the amino acid sequence GPQPAGEQGPRGDR 
located in the amino-terminal propeptide of type II procollagen [46]
[46]
PIIANP Amino terminus propeptide 
of type II procollagen, splice 
variant A
Cartilage formation. An ELISA using rabbit polyclonal antibodies raised to recombinant 
exon-2 of the amino-terminal propeptide of type II procollagen 
[71]
CPII C-propeptide of type II collagen Cartilage formation. EIA using rabbit polyclonal antibodies binding to the C-propeptides 
of type II collagen, that is, a marker of collagen synthesis. Manufacturer: Ibex, Canada
[161]
9A4/5109 Type II collagen Cartilage degradation. The collagenase-derived neoepitope GEGAAGPSGAEGPPGPQG775 
containing the carboxyl terminus of the long three-quarter fragment. mAb 5109 detects 
the fi  rst underlined sequence, mAb 9A4 the second (neoepitope) 
[162]
CTX-II Type II collagen Cartilage degradation. Competition ELISA using mAb F4601 recognizing the 
C-telopeptide neoepitope EKGPDP (manufacturer: IDS, UK) and mAb 2B4 recognizing the 
C-telopeptide neoepitope EKGPDP 
[42,163]
uTIINE Type II collagen Cartilage degradation. An LC-MS/MS assay using mAb 5109 (see above) to affi   nity purify 
fragments subjected to MS/MS. Detects a collagenase-derived 45-mer containing the 
carboxyl terminus of the long three-quarter fragment 
[53,54]
HELIX-II Type II collagen Cartilage degradation. A competition ELISA using polyclonal rabbit antibodies 
recognizing the neoepitope 622ERGETGPP*GTS632, where P* denotes hydroxyproline. 
However, a recent publication has highlighted unspecifi  cities [164]
[164-166]
C2C Type II collagen fragment Cartilage degradation. EIA using a monoclonal antibody recognizing the carboxyl 
terminus of the three-quarter piece of the degraded alpha1(II) chain. Manufacturer: Ibex, 
Canada
[167,168] 
C1,C2 Type II collagen fragment Collagen degradation. EIA using rabbit polyclonal antibodies binding to the carboxy-
terminal (COL2-3/4C(short)) neoepitope generated by cleavage of native human type II 
collagen by collagenases. Cross-reactivity to type I collagen 
[169]
PIIINP Amino terminus propeptide of 
type III procollagen
Collagen type II formation. RIA using polyclonal antibodies recognizing PIIINP. 
Manufacturer: Orion Diagnostic, Finland
[170] 
Continued overleaf
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whereas collagen type II is degraded by MMPs [40]. Th  e 
action of these proteases results in the release of collagen 
and aggrecan peptide fragments that can be measured by 
ELISA-type assays both in vitro and ex vivo [17] 
(Figure 4). Since collagen type II is the most abundant 
protein in cartilage, several diﬀ  erent degradation frag-
ments of collagen type II have been identiﬁ  ed as useful 
for monitoring the impact of joint inﬂ  ammation  on 
cartilage [17,41].
One example of a novel biochemical marker based on 
neoepitopes [16] is CTX-II, an MMP-generated neo  epi-
tope derived from the carboxy-terminal part of type II 
collagen [42,43]. Measurement of CTX-II has proven 
useful for monitoring degradation of type II collagen in 
experimental models assessing cartilage degradation 
[17,42,43]. Cartilage degradation and formation can be 
eﬃ   ciently studied in ex vivo cultured explants of bovine 
articular cartilage [40,44-47]. In this model, a high rate of 
cartilage degradation can be induced, for example, by the 
combination of TNF-α and oncostatin M, which induce 
cartilage degradation in a time- and concentration-
dependent manner. Th  e role of MMPs is demonstrated 
by the abrogation of cytokine- induced CTX-II release by 
the addition of the MMP inhibitor GM6001, but not the 
cysteine proteinase inhibitor E64. Further, biochemical 
studies showed that both MMP-9 and MMP-13 had the 
ability to generate CTX-II fragments [40]. In addition, 
immunohistochemical localization of CTX-II revealed 
that it is highly present in areas corresponding to 
proteoglycan depletion in TNF-α- and oncostatin M-
treated explants [40]. Additional analysis of CTX-II 
demon  strated that it was localized in the damaged areas 
of the articular cartilage [48-50]. In clinical studies, high 
levels of CTX-II have been shown to be associated with 
the diagnosis of OA and to predict progression of RA and 
OA joint damage [51]. Th  us, the assay for this MMP-
generated collagen type II neoepitope, CTX-II, is an 
example of a clinically and pathologically validated indi-
cator of cartilage degradation, although its responsiveness 
to therapeutic intervention continues to undergo inten-
sive investigation. With further charac  ter  i  zation in pros-
pective clinical trials, the CTX-II assay may provide an 
example that assays for neoepitopes generated by a 
speciﬁ  c combination of enzyme and matrix molecules 
are potentially relevant for monitoring risk of joint 
damage and impact of therapy. Th  e development of 
assays to assess cartilage degradation and formation is 
not limited to just CTX-II (Table 4). Degradation markers 
include urinary TIINE, serum C2C, C1C2, Coll-2-1, 
ICTP and HELIX-II, and synthesis markers include 
PIINP and PIIANP, as they are based on propeptides. 
COMP and YKL-40 have also been used to assess 
cartilage degradation, but have also been characterized to 
detect matrix turnover [17,19,45,47,52-74].
Bone turnover markers
Bone turnover is a continuous process that ensures 
calcium homeostasis and bone quality [75]. Th  e total 
skeleton is completely replaced every 10 years on average, 
Table 1. Continued
Assay Target molecule Short description
Evidence of 
potential 
usefulness 
Glc-Gal-PYD Glucosyl-galactosyl-pyridinoline Synovial infl  ammation. HPLC method for determination of the non-reducible collagen 
cross-linker glucosyl-galactosyl-pyridinium present in synovium and absent in bone 
cartilage and other soft tissue 
[171]
Serum HA Hyaluronic acid  Cartilage turnover. Based on HA binding protein isolated from bovine cartilage. 
Manufacturer: for example, Pharmacia, Sweden
YKL-40 Human glycoprotein 39 Cartilage turnover. RIA using polyclonal antibodies to a 40 kDa glycoprotein. A combined 
monoclonal capture and polyclonal (rabbit) detector sandwich assay is available. 
Manufacturer: Quidel Corporation, US
[172]
OC Osteocalcin Bone formation. Numerous assays available
MMP-3 and 
MMPs
Varous cell types  Numerous assays available [173,174]
DKK1/Sclerostin  Dkk-1 Measurement of Wnt signaling [175,176]
TRACP 5a Macrophages Infl  ammation [111]
TRACP 5b Osteoclasts  Osteoclast number. mAb to TRAcP 5b, which may be specifi  c for osteoclasts but not their 
activity
[74,111, 
177,178]
Cat K Osteoclasts Osteoclast number [110]
CRP, C-reactive protein; EIA, enzyme immunoassay; HA, hemagglutinin; LC, liquid chromatography; mAb, monoclonal antibody; MMP, matrix metalloproteinase; MS/
MS, tandem mass spectrometry; RIA, radioimmune assay. Modifi  ed and extended from [179].
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reﬂ  ecting changes in endocrine function as well as the 
eﬀ  ects of disease, drugs, and nutritional deﬁ  ciencies [76]. 
Perturbation of this delicate balance leads to pathological 
conditions such as OP and fracture risk, that is, bone 
loss. Bone turnover is mediated by activated osteoclasts, 
which degrade the established bone matrix, and 
osteo  blasts, which form new bone matrix, two processes 
that, under normal circumstances, are tightly coupled 
and balanced [77]. Th  e primary osteoclast driver is 
RANKL [78], although co-stimulators such as the 
cytokines IL-1β, IL-6 and/or TNF-α co-stimulate 
osteoclasts to secrete cathepsin K into the resorption 
lacunae [79,80], resulting in degradation of the organic 
Table 2. Biochemical markers in rheumatoid arthritis clinical trials: selected studies evaluating biochemical markers
Reference N Design/study if named Therapy Markers evaluated Results/timeframe
[168] 47 Open, single arm Adalimumab MMP-1, -3; COMP Decrease at 2 years only
[55] 49 Open, single arm Infl  ixamab (32)/etanercept (17) COMP Decrease at 3 months
[169]  68 Open, single arm Infl  ixamab Osteocalcin Increase weeks 2 to 6
P1NP Increase weeks 2 to 6
BAP No change
CTX-I No change
ICTP Decrease week 6
[170]  102 Open, single arm Infl  ixamab  Osteocalcin No change
CTX-I Decrease weeks 14 to 42
RANKL Decrease week 14
OPG No change
[24] 144 Post hoc, substudy in 
DB RCT
Infl  ixamab (two dose levels) 
versus MTX
CTX-I No change
Col2-3/4c No change
MMP-3 Decrease week 2
[98]  139/138 24-week DB RCT, MTX 
versus two dose levelsa
Tocilizumab  Osteocalcin Increase high dose
CTX-I Decrease both doses
ICTP Decrease both doses
PIIANP Decrease, dose-related
HELIX-II Decrease, dose-related
MMP-3 Decrease, dose-related
[171] 132/124 DMARD monotherapy Sulfasalazine, MTX, and 
adjunctive corticosteroids
MMPs, TIMP-1 COMP, 
glu-gal-pyr CTX-II
2 years, AUC measurements; 
MMP-3 + CTX-II, AUC was 81% for 
predictive accuracy 
[172] 155 DMARD monotherapy Sulfasalazine, MTX, and 
adjunctive corticosteroids
CTX-I, CTX-II Normalization of CTX-II predicted 
RA intervention effi   cacy 
[106]  48 1-year, open, single arm 
(with BMD)b
Infl  ixamab  P1NP No change weeks 6 and 52
CTX-I Decrease week 6
ICTP Decrease week 52
CTX-II No change
[109] 66 1-year, open, single arm, 
with X-rays at baseline 
and week 52c
Infl  ixamab CTX-II No change
Glc-Gal-PYD No change
[110,111] 145/157 1-year, open RCT/X-rays 
(SAMURAI)
Tocilizumab (anti-IL-6R) Osteocalcin Increase
NTX Decrease
PIIANPd Decrease
MMP-3d Decrease
aChanges with anti-IL-6R evident within 4 to 16 weeks, and at week 24 for CTX-I. bStable bone mineral density at month 12. cPatients with progressive joint damage 
had higher baseline levels. dWith hsCRP, modest correlation with progression of joint damage. AUC, area under the curve; BAP, bone alkaline phosphatase; COMP, 
cartilage oligomeric protein; CTX-I, C-terminal telopeptide of collagen type I; CTX-II, C-terminal telopeptide of collagen type II; DB, double blinded; DMARD, disease-
modifying antirheumatic drug; hsCRP, high-sensitive CRP; ICTP, type I collagen; MMP, matrix metalloproteinase; MTX, methotrexate; NTX, N-terminal telopeptide 
of collagen type I; OPG, osteoprotegerin; PIIANP, amino terminus propeptide of type II procollagen, splice variant A; PINP, amino terminus propeptide of type I 
procollagen; RA, rheumatoid arthritis; RANKL, receptor activator of NF-kB ligand; RCT, randomized controlled trial; TIMP, tissue inhibitor of metalloproteinases.
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protein in bone [75], and its degradation by cathepsin K 
leads to the release of the CTX-I or N-terminal telo-
peptide of collagen type I (NTX) neoepitope [81,82] 
(Figure 5). CTX-I levels increase in line with elevated 
levels of IL-6 after the menopause, indicating increased 
osteoclast activity and bone resorption [83,84]. CTX-I 
can be measured in both urine and serum and decreases 
rapidly in response to anti-resorp  tive treatment in OP 
[84-86]. Decreased CTX-I levels within 4 weeks of 
initiating anti-resorptive therapy corre  late with BMD 
increase at 1 year, demonstrating the eﬃ   cacy  of  the 
intervention [87-89]. As a result, CTX-I is being used in a 
large number of studies [88-93] to monitor the eﬃ   cacy of 
anti-resorptive therapies.
In RA a variety of factors, such as the impact of 
systemic inﬂ   ammation, corticosteroid use, and meno-
pause, may inﬂ  uence bone resorption, bone turnover and 
skeletal status over time. Activated osteoclasts participate 
in altered bone balance since absence of osteoclasts or 
absence of osteoclast activities will lead to attenuation of 
bone resorption but only modest eﬀ   ects on cartilage 
degradation [3,94,95]. Th  e role of cathepsin K has been 
extensively studied, and the data are somewhat conﬂ  ict-
ing for RA [40,96-98]. Levels of cathepsin K are in  creased 
in RA, indicating that it can be used as a marker [99,100], 
although cathepsin K does not appear to be the primary 
enzyme driving bone destruction in RA [98,101,102]. 
CTX-I levels correlate only to some extent with joint 
damage in RA, and are likely also inﬂ  uenced by loss of 
skeletal structure/osteopenia/OP, which are also 
prevalent in RA [22,103,104]. MMPs also play a role in 
inﬂ   ammation-associated bone loss [105,106]. Studies 
showing that the MMP-derived collagen type I fragment 
ICTP is increased in RA may indicate that osteoclasts 
induce MMP-mediated matrix degradation under these 
circumstances [82,107,108]. Inﬂ  iximab and tocilizumab 
treatment have been shown to reduce ICTP levels, as well 
as osteoclast numbers [103,109], consistent with osteo-
clast MMP-mediated bone degradation in RA. However, 
a direct link between the production of ICTP and 
osteoclasts has not been demonstrated yet.
As illustrated in Figure 5, a range of diﬀ  erent markers is 
available for assessing bone balance in RA. Th  e most 
Table 3. Biochemical markers in rheumatoid arthritis clinical trials: selected studies evaluating MRI-based measures and 
biochemical markers 
  Reference  N  Design/study if named  Image modality  Markers evaluated  Results
  [180]  84  Longitudinal analysis  MRI and X-ray  sCTX-I and uCTX-II sOPG, sYKL-40,   sCTX-I and uCTX-II were signifi  cant
          sCOMP and sMMP-3  predictors of progressive joint destruction
  [181]  377  Cross-sectional analysis  MRI  CTX-II  Correlation of uCTX-II with BME
  [155]  98  Cross-sectional analysis  MRI  COMP, MMP-3, CRP  COMP was elevated in those with bone 
           erosions
  [182]  72  Longitudinal analysis  MRI  IL-6, VEGF, YKL-40, CRP and ESR  Only IL-6 correlated with disease 
           progression
BME, bone marrow edema; COMP, cartilage oligomeric protein; CRP, C-reactive protein; CTX-I, C-terminal telopeptide of collagen type I; CTX-II, C-terminal telopeptide 
of collagen type II; ESR, erythrocyte sedimentation rate; MMP, matrix metalloproteinase; OPG, osteoprotegerin; s, serum; u, urinary; VEGF, vascular endothelial growth 
factor.
Table 4. Parameters for optimal use and interpretation of markers
Biological parameters  Sampling parameters   Analyte features  Assay format  Assay parameters  Study parameters
Food intake [183]  Sample acquisition  Active enzyme  Competitive assay  Dilution recovery  Mode of action
Diurnal variation [184-188]  Sample matrix (serum,   Latent enzyme  Sandwich assay  Buff  er robustness  Duration of study
  urine, plasma or 
 synovial  fl   uid)
Seasonal variation  Anticoagulant (EDTA,   Total protein  Monoclonal or  Range of quantization  Onset of action
  heparin, citrate)    polyclonal antibody
Joint activity [189,190]  Freeze-thaw cycles  Fragment of the   Multiplex or other  Sensitivity and limit of  Number of samples, 
    protein [9]  technique   detection  sampling frequency 
      (time  course)
Medical condition  Shipping and storage     Sample volume  Specifi  city and  Patient populationa
  conditions    selectivity  of  pathology 
     and  parameter
Compilation of parameters known to infl  uence biological variation or analytic performance of a given biochemical marker. These parameters include, but are not 
limited to, biological variation or analytical performance of a given biochemical marker. aAge, gender, menopause status, ethnicity, duration of rheumatoid arthritis, 
prior treatments such as TNF antagonists, concomitant medications such as corticosteroids, estrogen, SERMs, and bispohosphonates, and comorbidities such as 
osteoporosis, diabetes, and hypertension with or without renal insuffi   ciency.
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Page 10 of 20important markers are those of bone formation (PINP, 
osteocalcin, bone speciﬁ  c alkaline phosphatase (BSAP)) 
and bone resorption (for example, NTX and CTX), while 
assessment of osteoclast numbers by levels of the 
enzymes TRACP 5b and cathepsin K has more recently 
provided additional information complementary to bone 
resorption markers [74,110]. Another TRACP isoform, 
TRACP 5a, is a macrophage marker, and appears to 
corre  late with inﬂ  ammation [111]. Circulating levels of 
the formation marker PINP correlate with histomorpho-
metric indices of bone formation [17]. Osteocalcin levels 
are characteristically low in RA, associated not only with 
systemic bone loss but also corticosteroid treatment, and 
levels may stabilize or increase with eﬀ  ective control of 
inﬂ  ammation [112-114].
In conclusion, the inﬂ  amed joint is composed of several 
tissues, each of which is subject to degradation and 
dysregulated collagen and matrix metabolism, in contrast 
to a normal joint where the balance between formation 
and degradation is tightly controlled. Changes in bio-
chemical markers generated as a result of dysregulated 
metabolism may be useful for timely detection of changes 
in response to treatment in order to limit joint damage 
and bone loss in RA.
Currently available biochemical markers of joint 
damage
Th  e strategy for developing biochemical marker assays 
has evolved with experience in applying results from 
disease diagnosis and prognosis as well as from 
monitor  ing the eﬀ   ects of treatments for conditions 
commonly associated with joint damage. Th   e selection of 
particular assays depends on the objectives for study, but 
in most settings these include: examination of the 
mechanism of action to verify potential beneﬁ  ts  in 
limiting joint damage; prediction of risk of joint damage; 
diagnosis of ongoing bone and/or cartilage degradation 
in joints; and monitoring for timely detection of onset of 
action and maintenance of eﬀ  ect to limit joint damage.
Currently available and commonly used biochemical 
marker assays are described in Table 1. Th  is is not 
intended to be an exhaustive list; rather, it is intended to 
orient the reader to assays that have been commonly 
reported in clinical studies in arthritis, together with 
several assays that are currently being examined for 
improvements to meet the above objectives.
Biological marker assays for detection of tissue 
turnover in the human joint
Biochemical markers in ankylosing spondylitis - examining 
unique features of dysregulated bone and cartilage 
metabolism
Due to the paucity of information provided by standard 
clinical and laboratory parameters to guide treatment 
decisions, several of the biomarkers studied in RA have 
been analyzed in other inﬂ   ammatory joint diseases, 
particularly spondyloarthritis (SpA), on the basis that 
these disorders may share aspects of pathophysiology 
with RA. Th   ere has been particular interest in evaluating 
biomarkers in AS that reﬂ  ect disease activity and predict 
Figure 5. In bone, cell activation, cell diff  erentiation, matrix production, matrix degradation and the enzymes mediating that 
degradation may be measured by diff  erent markers. Each marker provides unique information and may indicate both pathological aspects 
and serve as a surrogate measure of the mode of action and potential effi   cacy of therapeutic interventions [85]. BSAP, bone specifi  c alkaline 
phosphatase; CTX, C-terminal telopeptide of collagen; ICTP, collagen type I fragment; NTX, N-terminal telopeptide of collagen type I; OC, 
osteocalcin; OPG, osteoprotegerin; PICP, carboxyl terminus propeptide of type I procollagen; PINP, amino terminus propeptide of type I procollagen; 
RANK, receptor activator of NF-kB; RANKL, receptor activator of NF-kB ligand. Figure adapted with permission from [85].
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Page 11 of 20structural progression [13,15,21,115]. For disease activity, 
CRP and ESR lack the sensitivity seen in RA, as these 
markers are elevated in only about 50% of ankylosing 
spondylitis (AS) patients [116]. Unlike RA, they also 
correlate poorly with clinical measures of disease activity, 
although good correlations have been noted with MRI 
evidence of inﬂ   ammation in the spine [117,118]. In 
contrast to RA, they do not appear to predict progression 
of structural damage, although similar to RA, CRP does 
predict clinical response to anti-TNF therapy [119,120].
Th   e primary biomarker reﬂ   ecting tissue turnover 
related to inﬂ  ammation in AS that has been analyzed is 
MMP3. Most studies have shown lower levels of MMP3 
in SpA than in RA. Levels are elevated mainly in patients 
with concomitant peripheral joint inﬂ  ammation  com-
pared to those with only axial inﬂ  ammation, and levels 
correlate with the histopathological grade of inﬂ  amma-
tion [121,122]. As for RA, there is evidence that levels of 
MMP3 can predict progression of radiographic changes, 
although for AS this means new bone formation rather 
than the erosive changes documented in RA [123]. Th  is 
ﬁ  nding is one observation that supports the concept of a 
link between inﬂ  ammation and ankylosis in AS. Reduc-
tions in MMP3 levels following anti-TNF therapy corre-
lated with reductions in CRP, although MMP3 levels have 
not been shown to predict clinical response [124].
Biomarkers reﬂ   ecting cartilage turnover have been 
analyzed in limited cross-sectional studies of patients 
with AS. Elevated levels of CPII and the aggrecan 846 
epitope were observed, as they were in RA [125], and 
normalization was seen with anti-TNF therapy [126]. 
One study has shown that urinary CTX-II may predict 
progression of structural damage in AS, as also docu-
mented for RA [127]. However, unlike RA, the collagen II 
degradation markers C2C and C1-2C were not elevated.
Assessment of biomarkers reﬂ  ecting bone turnover in 
SpA have shown variable results depending on the stage 
and activity of disease, but most studies have reported 
lower levels for markers of bone resorption than in RA 
[128]. A major inhibitor of osteoblastogenesis, DKK-1, is 
markedly elevated in RA but is not predictive in AS [125], 
while sclerostin is increased in RA and reduced in AS 
[126]. Th   ese changes are consistent with the excess bone 
formation observed in AS and impaired bone formation 
in RA.
In the current context, this use of biochemical markers 
in AS emphasizes that biochemical markers of bone and 
cartilage may be applied to SpA in well-controlled 
settings and studies.
Major clinical fi  ndings with selected interventions 
and cohort studies
Bone and cartilage biomarkers have been used with 
various levels of success in both degenerative and 
inﬂ   am  matory joint disease. Table 2 shows those 
applicable to RA in combination with X-ray imaging and 
Table 3 provides the current available publications on 
MRI and biochemical markers in RA. Th   ese tables clearly 
indicate that a subset of markers have already proven 
useful for investigating eﬃ     cacy in RA, although 
surprisingly few combinations of MRI and biochemical 
markers are currently used. Th  ese tables also do not 
constitute a full list of relevant studies; important 
information is available in other publications to 
complement the condensed infor  mation here 
[19,20,22,51,104,123,126,127,129-137].
Strategies for use of biochemical markers to 
enhance the benefi  t:risk ratio of RA therapies
Th   e lack of consensus on the optimal biochemical marker 
combination in RA is understandable given the varying 
outcomes from diverse studies in which their predictive 
value has been assessed. However, these diﬀ  ering out-
comes are likely due, at least in part, to diﬀ  erences in 
patient populations, such as varying duration of RA, and 
confounders, such as current and prior treatments, 
concomitant corticosteroids and other medications, as 
well as comorbid conditions (Table 4). Typically, studies 
with biologics with novel and unique mechanisms of 
action often recruit patients who have failed to respond 
to one or more therapies and were receiving a variety of 
concomitant medications. Th  us, even though patient 
populations at ﬁ  rst glance may seem somewhat similar, 
important diﬀ  erences exist and these need to be carefully 
considered when interpreting results.
Based on our current knowledge on RA, diﬀ  erent 
marker combinations may be useful at diﬀ  erent disease 
stages for identifying severity and risk of progression of 
joint damage. Th   is concept is illustrated in Figure 6a, and 
elaborated in Figure 6b-d. However, the use of bio-
chemical marker proﬁ  les to identify individual patients 
who will respond to a particular intervention, or are more 
likely to experience rapid progression of joint damage, 
still remains a major challenge.
Th   e pathology of RA appears to consist of a variety of 
diﬀ  erent phenotypes. If RA is left un-segmented and the 
population treated as a whole, the proportion of patients 
experiencing remission is relatively low in most clinical 
trials. As illustrated in Figure 6b, if a biomarker combi-
nation can identify a subset of patients representing a 
given phenotype who will respond to treatment, or 
demonstrate a superior response to a speciﬁ  c therapeutic 
intervention, then response rates in this patient subset 
will be far greater than those in the unstratiﬁ  ed popu-
lation. Th   is is an important socio-economic opportunity. 
By targeting the optimal treatment to patients who will 
derive the most beneﬁ  t, the most favorable beneﬁ  t:risk 
ratio will be obtained.
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poses and questions need to be carefully investigated, as 
illustrated in the ﬁ  gures in this paper. Combinations may 
depend on the duration and stage of disease in addition 
to the disease activity and associated eﬀ  ects on bone and 
cartilage tissues. It is now recognized that anti-TNF 
therapies may limit joint damage, even in clinical non-
responders, and responders to DMARD treatment may 
continue to experience ongoing joint damage, albeit at a 
slower rate [23,138]. Th  us, a speciﬁ   c combination of 
biochemical markers may not enable discrimination 
between clinical responders and non-responders for both 
radiological progression and patient assessment schemes 
as outlined by the American College of Rheumatology 
responder criteria or Disease Activity Score systems. Th  is 
feature of current therapies remains a further challenge 
for the use of ‘optimal’ combinations of biochemical 
markers and highlights the potential usefulness of bio-
chemical markers of active joint damage.
Lastly, as illustrated in Figure 6c,d and as discussed for 
the Burden of Disease, Investigative, Prognosis, Eﬃ   cacy 
of Intervention and Diagnostic (BIPED) categorization of 
biochemical markers [139], diﬀ   erent questions can be 
addressed by using these tools. As illustrated in Figure 6c, 
prognostic markers are those able to predict who will 
progress most rapidly. Th  is is an important part in 
identiﬁ  cation of those in most need of treatment. Th  e 
prognostic marker may also allow for identiﬁ  cation of 
particular patient phenotypes that will respond to treat-
ment (Figure 6a,b). A marker of eﬃ   cacy as illustrated in 
Figure  6d is a measurement at baseline or a temporal 
measurement compared to baseline, allowing the 
Figure 6. Schematic of the use and interpretation of biochemical markers. (a) Rheumatoid arthritis (RA) may consist of many diff  erent 
subphenotypes, with similarities and dissimilarities, as illustrated by the overlap and non-overlap of the diff  erent colored circles. If this population 
is left unsegmented, and the population treated as a whole, a relatively low number of responders may be identifi  ed. (b) A biomarker combination 
may identify a subset of patients representing a given phenotype that will respond to treatment, or respond preferentially to a particular 
therapeutic intervention, increasing overall response rates. (c,d) Diff  erent questions can be addressed by the use of biochemical markers. Each may 
require a diff  erent biomarker subset. (c) Prognostic markers are those able to predict which patients will progress most rapidly. This is important for 
identifying those patients most in need of treatment. (d) A marker of effi   cacy will allow interpretation of potential effi   cacy far earlier than traditional 
radiological-based changes.
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radiological-based techniques, such as illustrated in 
Figure  2. In particular, in the ﬁ   eld of certain bone 
diseases, CTX-I is a surrogate marker of eﬃ   cacy, aiding 
the prediction of a patient’s response to treatment before 
standard radiological assessment is possible [16].
Biomarker classifi  cation
Not all biochemical markers provide the same infor-
mation. Some may be diagnostic, whereas others may aid 
prognosis, and others indicate the potential eﬃ   cacy of 
interventions. Th  us, one biomarker that may fail in one 
function or scenario may provide important information 
in another. Th  is highlights the need for a framework to 
understand terminologies in the development and use of 
biochemical markers. Th  e recently proposed BIPED 
classiﬁ  cation, developed by the Osteoarthritis Biomarkers 
Network, which is funded by the US National Institutes 
of Health, has further highlighted the need for under-
standing biomarkers and their use [139]. Th  e BIPED 
classiﬁ  cation provides speciﬁ  c biomarker deﬁ  nitions with 
the goal of improving the development and analysis of 
OA biomarkers and of communicating advances within a 
common framework. Brieﬂ  y, the ﬁ  ve deﬁ  nitions for OA 
are burden of disease, investigative, prognostic, eﬃ   cacy 
of intervention, and diagnostic. Burden of disease 
markers assess the severity or extent of disease, for 
example, severity within a single joint and/or the number 
of joints aﬀ  ected. Investigative is an investigative marker 
with insuﬃ   cient information to allow inclusion into one 
of the existing biomarker categories. Th  e investigative 
category includes markers for which a relationship to 
various normal and abnormal parameters of cartilage 
extracellular matrix turnover has not yet been established 
in human subjects. Th  e key feature of a prognostic 
marker is the ability to predict the future onset of OA 
among persons without OA at baseline or the progression 
of OA among those with the disease. An eﬃ   cacy  of 
intervention biomarker provides information about the 
eﬃ   cacy of treatment among persons with OA or those at 
high risk for development of OA. Diagnostic markers are 
deﬁ   ned by the ability to classify individuals as either 
having or not having a disease.
Th   is very simple yet elegant classiﬁ  cation could be used 
in other disease indications, such as RA, to foster optimal 
use, and avoid miscommunication of the beneﬁ  ts  of 
selected biochemical markers.
Confounders that infl  uence the application and 
interpretation of biochemical marker assay results
As many factors aﬀ  ect the measurement and inter  pre-
tation of changes in levels of biochemical markers, a 
critical review of sample acquisition, storage and assay 
parameters must be undertaken to optimally assess the 
reliability of biochemical marker analysis. Some of these 
considerations are highlighted in Table 4, and the reader 
is referred to the referenced papers for an in-depth 
discus  sion of the individual assays and guidance for 
appropriate, evidence-based interpretation of their 
results. Multiple biological or analyte-related factors, 
assay speciﬁ  cations, study parameters and the context in 
which the results are interpreted are often under-
estimated and ignored in the study design phase but can 
have tremendous impact on the ﬁ  nal interpretation of the 
results.
Technical performance strategies for reproducible and 
reliable biochemical marker analysis include, but are not 
limited to, the following parameters. Th  e analytical 
method must be validated by the laboratory for each 
biomarker used in a clinical study before the laboratory 
begins analyzing samples from the study. Although 
manu  facturers’ kit inserts provide useful assay para-
meters, it is mandatory that each laboratory veriﬁ  es it 
can reproduce these parameters. Th  e validation should 
be performed on the same sample matrix (serum, plasma, 
urine or synovial ﬂ  uid) as collected in the clinical study. 
Results obtained from serum are not necessarily the same 
as those from plasma, for example. Th  e analytical 
validation should include calibration curves, with at least 
six non-zero standards, intra- and inter-precisions and 
accuracy, the range of quantiﬁ   cation and sensitivity 
(lower and upper limits of quantiﬁ   cation, limit of 
detection, speciﬁ   city and selectivity, recovery, stability 
and dilution linearity. Th  eoretically, to estimate intra- 
and inter-run accuracy and stability, ﬁ  ve  diﬀ  erent 
validation samples should be analyzed in duplicate or 
more in at least six diﬀ   erent runs. One of the major 
problems with assays (especially microtiter plate-based 
assays) is reagent-lot variation, indicating a lack of assay 
robustness. Quality control (QC) samples with pre-
deﬁ  ned validated ranges must be analyzed together with 
the calibrators and the study sample in each run. Th  ese 
QC samples must be prepared in the same matrix as the 
study samples and, whenever possible, must cover the 
range of the standards curve (lower, middle and upper 
limits). Th   e run must be accepted (or rejected) based on 
the QC acceptance criteria (typically, a 4-6-X rule, where 
X is a selected percent deviation from nominal value), 
but also on the results of the calibration standards (back-
calculated value within 20% of nominal). Lastly, whenever 
possible, batches of samples collected during the ﬁ  rst 
visits of the patients, when changes in biomarker levels in 
response to drug treatment could be theoretically 
detected, should be assayed together in the same run. 
Th   is should further minimize inter-assay variation.
Th  ese examples serve to highlight that biochemical 
marker analysis includes a range of parameters that need 
to be carefully considered and accounted for in optimal 
Karsdal et al. Arthritis Research & Therapy 2011, 13:215
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Page 14 of 20assay performance, which eventually will impact the 
results of the clinical trials.
Conclusion
RA is often characterized by progressive joint damage 
that, if not arrested by treatment, often leads to sub-
stantial limitation of function and progressive disability. 
It is evident that the nature of progressive joint damage 
varies considerably, with some RA patients experiencing 
more rapid progression than others, based on underlying 
pathobiology, levels of response to treatment, duration 
and stage of disease, as well as comorbidities and conco-
mitant medications. Patients with rapidly progressing 
joint damage may particularly beneﬁ   t from early 
aggressive treatment with a biologic agent. Consequently, 
the identiﬁ  cation of patients with ongoing joint damage 
and assurance that treatment is limiting cartilage 
degradation and improving bone balance is important in 
preventing irreversible joint damage. Biological markers 
and clinical measures can be used to help identify this 
group of patients, including elevated CRP levels and the 
number of swollen and tender joints. Additional 
application of biochemical markers, which are able to 
sensitively detect ongoing joint damage, may facilitate 
the appropriate use of targeted therapy in RA and help 
reduce the progression of joint damage in these patients.
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